This article describes the 30-y history of nuclear medicine in Brazil, including reactors, production of radiopharmaceuticals, and trends.
200 kW and 2 MW. In 1961, a program was established to produce 131 I, and the reactor began to be operated at a constant power of 2 MW, 8 h per day and 5 d per week (1, 2) . In 1995, a program was established to start the immediate production of 153 Sm and to prepare the reactor to produce 99 Mo. As result of this decision, the operating schedule was changed to 64 h per week, from Monday through Wednesday, keeping the reactor power at 2 MW. Some modifications were introduced to comply with the new national legislation in order to operate continuously during 120 h per week at 5 MW. The burnup rate, which is currently 240 MW day (MWD), is expected to increase to 1,100 MWD.
The IPR-R1 (Instituto de Pesquisas Radioativas Reator 1), a 250-kW Training Research Isotope General Atomic (TRIGA) reactor operating at the Centro de Desenvolvimento de Tecnologia Nuclear (Nuclear Technology Development Centre), or CDTN, on the campus of the Federal University of Minas Gerais in the city of Belo Horizonte, is used mainly for research. It was the second Brazilian research reactor, with its first criticality reached in November 1960. This reactor operates 4 h per day, 5 d per week, and 40 wk per year. The integrated burnup of the reactor from its first criticality until now has been about 130 MWD (3, 4) . Because of the low nominal power, except for aging concerns, spent fuel is far from being a problem. The first fuel assembly replacement of the reactor was not expected to occur until 2010.
The third Brazilian research reactor is the Argonauta, located at the Instituto de Engenharia Nuclear (Nuclear Engineering Institute), or IEN, on the campus of the Federal University of Rio de Janeiro. Argonauta's first criticality was reached in February 1965. This reactor can operate at a maximum power of 1 kW during an hour or 500 W continuously. It is usually operated in the range of 170-340 W (5). Its accumulated burnup, since the first criticality, is about 0.25 MWD. As in the case of IPR-R1, because of the low nominal power, storage of spent fuel is not a problem. It is used mainly for training purposes, research, and sample irradiation.
The use of radioisotopes in research occurs mainly at CNEN's research institutes (IPEN, IEN, and CDTN), but also other research centers and universities use radioactive sources. The research is diverse, including nuclear physics, biol-ogy, agriculture, health, hydrology, and the environment. Small sources of 3 H, 14 C, 22 Na, 55 Fe, 63 Ni, 125 I, 226 Ra, 35 S, and 32 P are used. Since 1974, IEN has had a CV-28 cyclotron, which was originally used in physics and radioisotope production research and now is used mainly in the production of radiopharmaceuticals for diagnostic examinations. In 1998 the Institute adopted the Karlsruhe Iodine Production System (KIPROS) for the production of 123 I (6). This production routine provides conditions for labeling special molecules. The first one was 123 I-labeled metaiodobenzylguanidine (MIBG), whose main application is in cardiology.
PRODUCTION OF RADIOPHARMACEUTICALS
In 2000, one 18 F-FDG production unit from Ion Beam Applications was imported and connected to IEN's CV-28 cyclotron. Use of this unit began on an experimental basis, producing 18 F. Samples of FDG labeled with 18 F, which was considered the newest and most innovative technology in nuclear medicine (7,8), started to be sent to hospitals in Rio de Janeiro. Because of the short life, only 1.8 h, this radiopharmaceutical must be produced as near as possible to the application site (within ;200 km).
In 2003, after the installation of the RDS-111 cyclotron (CTI/Siemens), IEN stepped up the production of 18 F and, consequently, 18 F-FDG. This system is recognized worldwide for its reliability and simplicity of operation. With the RDS-111, IEN was able to produce 18 F-FDG in 2 independent ways, with different installations, 1 of them as a backup. The redundancy was created to guarantee the delivery process.
The CDTN inaugurated its radiopharmaceutical production unit in the first half of 2008 (9,10) and started the pilot production of 18 F-FDG in the second half of the year, reaching commercial production of this radiopharmaceutical in 2009.
PET Radiopharmaceuticals
PET is a complex and high-cost nuclear medicine technology. The diffusion of PET in Brazil is recent and still limited, but the fall of the federal monopoly on the production of radiopharmaceuticals in 2006 triggered a movement to multiply the number of cyclotron installations and the purchase of PET scanners, especially by the private health sector. The resulting increase in demand has placed pressure on the Brazilian National Health System to incorporate this type of examination into the reimbursement tables, requiring evidence-based updated appraisals to support the decision-making processes.
In the last decade, 18 F-FDG has become a breakthrough in nuclear medicine (9) . Associated with new-generation equipment for PET or SPECT, 18 F-FDG is now widely used in oncology, visualizing and distinguishing malignant from benign tumors as well as distinguishing primary tumors from metastases. In cardiology, one of its applications is assessing the level of damage to the heart that has undergone a cardiovascular accident. In neurology, PET technology can be applied to diagnose Parkinson, Alzheimer, and Tourette diseases and to visualize brain damage caused by drug consumption. PET technology began in 1981, when the first PET scanner became available. Currently, there are more than 500 centers operating mainly in the United States, Europe, and Japan. In the specific case of Brazil, the tropical diseases are an open field for research, with unpublished applications.
I-MIBG Radiopharmaceutical
MIBG is labeled at the IEN radiopharmacy laboratory using ultrapure 123 I produced at the KIPROS system. The 123 I is obtained by bombardment of a 124 Xe target with a 24-MeV, 20-mA proton beam in the CV-28 cyclotron. The labeling method is based on a nucleophilic substitution in an MIBG molecule. In order for the product to be used as a diagnostic agent, the radiochemical purity must be as high as 97%. Because of a half-life of only 13.2 h, 123 I-MIBG allows the diagnosis of heart diseases and tumors. However, 131 I-MIBG, because of a longer half-life (8 d), is more suitable for higher-dose treatment of tumors. With the production of ultrapure 123 I, IEN follows a worldwide trend to make short-half-life radioisotopes available for examinations and therapy.
DATA AND TRENDS
In terms of sales, Brazil is a major player in the radiopharmaceutical market despite considerable barriers to production and reimbursement. In 2009, Brazil sold almost 70 million Reais of 18 F-FDG. Converting this value to U.S. dollars, sales of 18 F-FDG in Brazil were approximately $35 million, compared with U.S. sales of $522 million in 2009. Despite having only 2 PET radiopharmaceutical facilities, Brazilian production was equal to 6.7% of the U.S. production from more than 30 PET facilities. This is an impressive feat. However, it is not clear that these facilities can continue to expand production to meet the growing demand for imaging using radiopharmaceuticals. The reliance on just 2 high-volume facilities for the entire national production of PET radiopharmaceuticals suggests an urgent need to increase the number of production facilities in Brazil.
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